Table 1.
Study Participants
| |
Patient ID |
|
Time |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gender | Status | ART | CDA* | CDA* | VL+ | HIV+ | Time Tx | Ag69e | ||
| HIV Control (n = 9) |
204 |
F |
Control |
N/A |
730 |
327 |
N/A |
N/A |
N/A |
54 |
| |
206 |
F |
Control |
N/A |
510 |
275 |
N/A |
N/A |
N/A |
69 |
| |
213 |
F |
Control |
N/A |
1021 |
382 |
N/A |
N/A |
N/A |
43 |
| |
214 |
F |
Control |
N/A |
1559 |
1294 |
N/A |
N/A |
N/A |
36 |
| |
215 |
M |
Control |
N/A |
380 |
290 |
N/A |
N/A |
N/A |
57 |
| |
218 |
M |
Control |
N/A |
674 |
241 |
N/A |
N/A |
N/A |
35 |
| |
222 |
F |
Control |
N/A |
ND |
ND |
N/A |
N/A |
N/A |
24 |
| |
225 |
F |
Control |
N/A |
ND |
ND |
N/A |
N/A |
N/A |
55 |
| |
226 |
F |
Control |
N/A |
1114 |
401 |
N/A |
N/A |
N/A |
61 |
| HIV ART-(n = 6) |
217 |
M |
HIV+ |
No |
307 |
1117 |
216000 |
9 yr |
None |
39 |
| |
224 |
F |
HIV+ |
No |
238 |
1072 |
90000 |
3 yr |
None |
39 |
| |
207 |
F |
HIV+ |
No |
151 |
385 |
55000 |
1.5 yr |
None |
59 |
| |
221 |
M |
HIV+ |
No |
381 |
1188 |
50000 |
9 yr |
None |
41 |
| |
223 |
F |
HIV+ |
No |
137 |
389 |
18000 |
1 yr |
None |
30 |
| |
212 |
M |
HIV+ |
No |
525 |
873 |
9000 |
1.5y |
None |
28 |
| HIV + ART + (n = 6) |
158 |
M |
HIV+ |
Yes |
873 |
1302 |
UD |
23 yr |
20 yr |
58 |
| |
166 |
M |
HIV+ |
Yes |
540 |
1041 |
UD |
13 yr |
13 yr |
53 |
| |
205 |
F |
HIV+ |
Yes |
1069 |
582 |
UD |
15 yr |
8 yr |
61 |
| |
208 |
F |
HIV+ |
Yes |
322 |
311 |
UD |
6 yr |
3 yr |
37 |
| |
219 |
F |
HIV+ |
Yes |
490 |
531 |
UD |
6 yr |
6 yr |
44 |
| 228 | M | HIV+ | Yes | 368 | 582 | UD | 9 yr | 9 yr | 39 | |
Clinical characteristics of study participants. * CD4+, CD8+ T cells/mL blood. † HIV RNA copies/mL blood. ART = antiretroviral therapy, Tx = treatment.